Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Ranibizumab Stories

2011-06-09 06:00:00

INCLINE VILLAGE, Nev., June 9, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today revised its guidance for the second quarter ending June 30, 2011, to approximately $122 million, as compared with actual results of $120 million for the second quarter of 2010, an anticipated one percent year-over-year increase. The revision to the earlier guidance of $128 million is due to a mathematical error. The forecasted growth is primarily driven by increased first quarter 2011 sales...

2011-06-07 01:30:00

TARRYTOWN, N.Y. and BERLIN, June 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye for the treatment of wet AMD, central retinal vein occlusion...

2011-06-01 06:00:00

INCLINE VILLAGE, Nev., June 1, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the second quarter ending June 30, 2011, of approximately $128 million, as compared with actual results of $120 million for the second quarter of 2010, an expected seven percent year-over-year increase. The forecasted growth is primarily driven by increased first quarter 2011 sales of Herceptin®, Lucentis® and...

2011-05-16 07:36:00

SAN MATEO, Calif., May 16, 2011 /PRNewswire/ -- On April 28, 2011 the New England Journal of Medicine released highly anticipated one-year results of the ongoing "Comparisons of Age-Related Macular Degeneration Treatments Trials" (CATT). AlphaDetail, Inc., a leader in global ophthalmology primary market research and influence network mapping, has conducted its latest AlphaPulse(TM) survey with 120 Ophthalmologists to gauge their reactions on the heels of this important news. Amy Tsang, a...

2011-04-28 21:14:23

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as the Food and Drug Administration-approved drug Lucentis for the treatment of AMD. The report, from the Comparison of AMD Treatments Trials (CATT), was published online today in the New England Journal of Medicine. CATT is funded by the National Eye Institute...

2011-04-28 11:48:00

CLEVELAND, April 28, 2011 /PRNewswire/ -- A new study published online today in The New England Journal of Medicine (NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab (Lucentis), the current Food and Drug Administration-approved drug for treating age-related macular degeneration (AMD). The results are from the landmark "Comparison of AMD Treatments Trials" (CATT) study, a pioneering comparative effectiveness trial made possible through funding by the National Eye...

2011-03-21 03:09:00

LONDON, March 21, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, announces today that its partner, Quark Pharmaceuticals, has received results from a prospective randomized Phase 2 trial, the DEGAS study. The study evaluated the safety and efficacy of PF-04523655 (RTP801I- 14) in patients with diabetic macular edema (DME). PF-04523655 incorporates Silence's AtuRNAi technology...

2011-03-18 17:12:00

FREMONT, Calif., March 18, 2011 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study. This study evaluated the safety and efficacy of PF-04523655 (RTP801I-14) in patients with diabetic macular edema (DME). 184 patients were randomly assigned to four treatment groups; three dose levels of PF-04523655...

2011-03-07 06:00:00

INCLINE VILLAGE, Nev., March 7, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the first quarter ending March 31, 2011 of approximately $83 million, as compared with actual results of $62 million for the first quarter of 2010, an expected 34 percent year-over-year increase. Included in first quarter revenue guidance is the $10 million settlement received from UCB Pharma S.A. (UCB) in January 2010 resolving all legal disputes between the...

2011-02-28 06:00:00

INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has entered into a definitive settlement agreement with Novartis that resolves all disputes between them. Under the settlement agreement, PDL agreed to dismiss its claims against Novartis in its action in Nevada court, which also includes Genentech, Inc. (Genentech) and F. Hoffmann-La Roche Ltd (Roche) as defendants. Novartis agreed to withdraw its opposition appeal in the...